Synaptogenix Stock (NASDAQ:SNPX)

Revenue Ownership Financials Chart

Previous Close

$2.53

52W Range

$2.32 - $8.78

50D Avg

$3.04

200D Avg

$4.07

Market Cap

$3.27M

Avg Vol (3M)

$29.19K

Beta

1.43

Div Yield

-

SNPX Company Profile

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

5

IPO Date

Dec 08, 2020

Website

SNPX Performance

SNPX Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-6.04M	$-26.36M	$-12.62M
Net Income	$-13.78M	$-5.46M	$-12.60M
EBITDA	$-6.04M	$-26.36M	$-12.61M
Basic EPS	$-1.18	$-0.78	$-2.51
Diluted EPS	$-1.18	$-0.78	$-2.51

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
RVPH	Reviva Pharmaceuticals Holdings, Inc.
ALZN	Alzamend Neuro, Inc.
CYTH	Cyclo Therapeutics, Inc.
ANVS	Annovis Bio, Inc.
INMB	INmune Bio, Inc.